PGxAI's Andromeda qualifies on Mayo Clinic Platform

PGxAI said its Andromeda decision-support tool is now a qualified solution on Mayo Clinic Platform, giving the company a structured path toward integration in clinical workflows. The move could help bring pharmacogenomics-driven prescribing support closer to everyday care and expand PGxAI’s access to provider evaluation and deployment pathways.

Why it matters: - PGxAI’s placement on Mayo Clinic Platform gives Andromeda a pathway toward provider-led evaluation and clinical workflow integration. - The qualification may make it easier for health systems to test medication guidance tools that combine pharmacogenomics, multi-omics data, and clinical context. - The company is positioning personalized prescribing as a way to improve therapy selection, dosing, medication safety, and outcomes.

What happened: - PGxAI announced on August 24, 2026, that Andromeda is now a qualified solution on Mayo Clinic Platform. - Andromeda is PGxAI’s first-in-class decision-support tool. - The solution is built for prescribing workflows inside electronic health records. - The platform qualification creates a structured route to integration in care delivery environments.

The details: - Andromeda uses a clinician-reviewable architecture. - The system combines pharmacogenomics, other multi-omics data, phenoconversion-related factors, drug-drug interactions, drug-condition interactions, clinical context, and real-world evidence in one medication guidance layer. - PGxAI designed the product for health systems, payers, laboratories, and biopharma. - The software aims to help care teams move from complex biological and clinical signals to actionable and auditable medication decisions. - Mayo Clinic Platform evaluates solutions for intended use, proposed value, and clinical and algorithmic performance. - Mayo Clinic Platform also provides infrastructure and an ecosystem for digital health developers working toward real-world clinical and administrative workflows.

Between the lines: - The announcement signals a push to make precision medicine easier to operationalize inside routine care, not just in research settings. - Mayo Clinic Platform’s qualification process adds a layer of credibility and technical readiness that can matter for adoption. - PGxAI is emphasizing transparency and clinician control, which may help address trust concerns around AI-assisted prescribing. - Steve Bethke said qualified solutions are supported by Mayo Clinic Platform’s ecosystem and technical infrastructure, enabling expedited validation and potential deployment into clinical and administrative systems. - Mike Zack, PGxAI’s CEO and co-founder, said the goal is to make the right medication and dose the starting point of treatment, with the final decision remaining with the clinician.

What’s next: - PGxAI now has a structured path toward deployment readiness through Mayo Clinic Platform. - The company can pursue provider-led evaluation and planning for integration into clinical workflows. - Further validation and potential deployment will depend on the separate terms and reviews tied to third-party products on Mayo Clinic Platform. - Mayo Clinic states that it does not endorse or warrant third-party products or services made available through Mayo Clinic Platform.